Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 10/20 | 0.38 |
| ▸ | BCHE | P06276 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645308 | 0.85 | NQO1 (0.44) | NQO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2252738 | 0.81 | NQO1 (0.50) | NQO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2257414 | 0.81 | NQO1 (0.50) | NQO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7835769 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7196807 | 0.80 | HTR1B (0.33) | — | |
| SCHEMBL2252262 | 0.80 | HTR1B (0.42) | ALDH1A1CYP2A6 | |
| SCHEMBL3694710 | 0.80 | HTR1B (0.33) | — | |
| SCHEMBL3693837 | 0.78 | CYP2D6 (0.32) | — | |
| Water SCHEMBL5028474 | 0.77 | MAPT (0.59) | NQO1KDM4EALDH1A1HSD17B10CA12 | |
| SCHEMBL5544427 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-05-28 | — | — | US | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| EP-0783486-B1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | DU PONT PHARM CO (US) | 1999-10-13 | — | — | EP | claimed |
| US-5932586-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| EP-0783486-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-16 | — | — | EP | claimed |
| US-5593994-A | ANTIINFLAMMATORY AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996010012-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-04-04 | — | — | WO | claimed |
| EP-2123695-B1 | METAL THIETANE COMPOUND, POLYMERIZABLE COMPOSITION COMPRISING THE COMPOUND, RESIN, AND USE OF THE RESIN | MITSUI CHEMICALS INC (JP) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-4716169-A | INOTROPIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-12-29 | — | — | US | disclosed |
| EP-0185345-A1 | Imidazo derivatives, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
| EP-0185346-A2 | Imidazo derivatives, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | NQO1 473/4885KDM4E 4268/4885ALDH1A1 197/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | NQO1 473/4885KDM4E 4268/4885ALDH1A1 197/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | NQO1 83/4885KDM4E 3693/4885ALDH1A1 934/4885 |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | CACNB2, CACNB1, CACNB4 | NQO1 4540/4885KDM4E 3253/4885ALDH1A1 4200/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | NQO1 473/4885KDM4E 4268/4885ALDH1A1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.